Journals / Dicle Tıp Dergisi / 2022 / Cilt: 49 - Sayı: 1

Results of Coupled Plasma Filtration Adsorption (CPFA) Treatment Applied to Critical COVID-19 Patients in Intensive Care Unit

Pages
66–76
Publication Date
2022-03-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The CPFA treatment removes the uncontrolled production of harmful cytokines/chemokines and toxic substances from the blood and shows promise in the treatment of the cytokine storm that develops in COVID-19 disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The novel coronavirus, called SARS-CoV-2, causes COVID-19 disease and began a pandemic on a global scale.
📊
Key Findings & Data:Uncontrolled cytokine production is observed especially in COVID-19 cases with severe progression and this situation is thought to be one of the causes of more severe disease progression and increased mortality.
💡
Conclusion & Impact:Conclusion: The CPFA treatment removes the uncontrolled production of harmful cytokines/chemokines and toxic substances from the blood and shows promise in the treatment of the cytokine storm that develops in COVID-19 disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Coronavirus · Coupled Plasma Filtration Adsorption · COVID-19 disease

Abstract

Objective: The novel coronavirus, called SARS-CoV-2, causes COVID-19 disease and began a pandemic on a global scale. Uncontrolled cytokine production is observed especially in COVID-19 cases with severe progression and this situation is thought to be one of the causes of more severe disease progression and increased mortality. In our study, we aimed to assess the efficacy of Coupled Plasma Filtration Adsorption (CPFA) treatment in situations with severe disease progression like sepsis, septic shock and multiple organ failure, considered to be secondary to cytokine storm, in COVID-19 disease. Methods: Our study retrospectively screened data from 20 patients admitted to our intensive care unit and administered CPFA. CPFA was administered as 10 hours each session and 2 sessions with 12 hours interval. Results: After our CPFA treatment, there were statistically significant ameliorations in clinical and laboratory findings like SOFA scores, mainly, Horowitz values, fever and IL-6 values. Conclusion: The CPFA treatment removes the uncontrolled production of harmful cytokines/chemokines and toxic substances from the blood and shows promise in the treatment of the cytokine storm that develops in COVID-19 disease.

🔖

Cite This Article

ERTÜRK, T., GÜVEN, B. B., ÜNLÜKAHRAMAN, G. K., ERSOY, A. (2022). Results of Coupled Plasma Filtration Adsorption (CPFA) Treatment Applied to Critical COVID-19 Patients in Intensive Care Unit. Dicle Tıp Dergisi, Cilt: 49 - Sayı: 1, 66–76. https://ajindex.com/articles/484894

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kurt NG, Çamcı M. COVID-19 and Other Viral Pneumonias. Dicle Tıp Dergisi / Dicle Med J. 2021; 48: 40-6. 2. https://coronavirus.jhu.edu/map.html (Last access: 30.12.2021
  2. D’Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the ‘cytokine storm’ for therapeutic benefit. Clin Vaccine Immunol. 2013; 20: 319–27
  3. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014; 383(9927): 1503-16
  4. McGonagle D, Sharif K, O’Regan A, Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev. 2020; 19: 102537
  5. Şit D, Kayabaşı H. SARS-CoV-2 ile İlişkili Akut Böbrek Hasarı. Dicle Tıp Dergisi / Dicle Med J. (2020) 47: 498-507
  6. Jin YH, Cai L, Cheng SZ, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020; 7: 4
  7. Bajema KL, Oster AM, McGovern OL, et al. Persons Evaluated for 2019 Novel Coronavirus- United States, January 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 166-70
  8. Panagiotou A, Gaiao S, Cruz DN. Extracorporeal therapies in sepsis. J Intensive Care Med. 2013; 28: 281-95
  9. Harm S, Gabor F, Hartmann J. Characterization of Adsorbents for Cytokine Removal from Blood in an In Vitro Model. J Immunol. 2015: 1-11
  10. Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020; 34: 327-31
  11. Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, Nemati M. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions. Life Sci. 2020; 257: 118102
  12. Huang Q, Wu X, Zheng X, et al. Targeting inflammation and cytokine storm in COVID-19. Pharmacol Res. 2020; 159: 105051
  13. Hassan J, Cader RA, Kong NCT, et al. Coupled plasma filtration adsorption (CPFA) plus continuous veno-venous haemofiltration (CVVH) versus CVVH alone as an adjunctive therapy in the treatment of sepsis. EXCLI J. 2013; 12: 681–92
  14. Dastan F, Saffaei A, Mortazavi SM, et al. Continues renal replacement therapy (CRRT) with disposable hemoperfusion cartridge: a promising option for severe COVID-19. J Glob Antimicrob Resist. 2020; 21: 340-1
  15. Berlot G, Agbedjro A, Tomasini A, et al. Effects of